FOLH1 and neoplasm: Based on the anti-tumor effects of I3A, Wang et al. developed a dual-targeted delivery system of I3A and doxorubicin, which targets prostate-specific membrane antigen (PSMA) and mitochondria, inhibiting PC growth and eliciting potent anti-tumor immune responses (Wang et al., 2022).